Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
BCRX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 13, 2026
Report Source: 2026 1st Quarter Report
BioCryst Pharmaceuticals Inc. Stock Analysis BCRX
United States Health Care Mid Cap Report: BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
Read More BioCryst Pharmaceuticals Inc (BCRX) Chart
Key Statistics of BioCryst Pharmaceuticals Inc (BCRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$9.18Volume
5.14MP/E Ratio (TTM)
8.8852 Week Range
Market Cap
2.13BAvg. Volume
4.31MDividend Yield
-Financial Metrics & Statements of BioCryst Pharmaceuticals Inc (BCRX)
FAQ's for BioCryst Pharmaceuticals Inc (BCRX)
- According to Musaffa’s Shariah screening methodology, BioCryst Pharmaceuticals Inc (BCRX) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes BioCryst Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in BioCryst Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of BioCryst Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of BioCryst Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of BioCryst Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.